First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis

Author:

Crespiatico Ilaria1ORCID,Zaghi Mattia2ORCID,Mastini Cristina1ORCID,D’Aliberti Deborah1ORCID,Mauri Mario1ORCID,Mercado Carl Mirko1ORCID,Fontana Diletta1ORCID,Spinelli Silvia1ORCID,Crippa Valentina1ORCID,Inzoli Elena3ORCID,Manghisi Beatrice3ORCID,Civettini Ivan3ORCID,Ramazzotti Daniele1ORCID,Sangiorgio Valentina3,Gengotti Michele1ORCID,Brambilla Virginia4,Aroldi Andrea13,Banfi Federica2,Barone Cristiana1ORCID,Orsenigo Roberto5,Riera Ludovica6,Riminucci Mara7ORCID,Corsi Alessandro7ORCID,Breccia Massimo8ORCID,Morotti Alessandro9ORCID,Cilloni Daniela9ORCID,Roccaro Aldo10ORCID,Sacco Antonio10ORCID,Stagno Fabio11,Serafini Marta12,Mottadelli Federica12,Cazzaniga Giovanni112,Pagni Fabio4,Chiarle Roberto131415,Azzoni Emanuele1ORCID,Sessa Alessandro2ORCID,Gambacorti-Passerini Carlo13ORCID,Elli Elena Maria3,Mologni Luca1ORCID,Piazza Rocco13ORCID

Affiliation:

1. 1Department of Medicine and Surgery, University of Milan-Bicocca, Monza, Italy

2. 2Neuroepigenetics Unit, Division of Neuroscience, Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele Scientific Institute, Milan, Italy

3. 3Hematology Division and Bone Marrow Unit, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico San Gerardo dei Tintori, Monza, Italy

4. 4Department of Pathology, University of Milan-Bicocca, Monza, Italy

5. 5Biomedical Research in Melanoma-Animal Models and Cancer Laboratory, Vall d'Hebron Research Institute, Vall d'Hebron Hospital Barcelona UAB, Barcelona, Spain

6. 6Department of Pathology, Azienda Ospedaliero Universitaria Città della Salute e della Scienza, Turin, Italy

7. 7Department of Molecular Medicine, Azienda Policlinico Umberto I, Sapienza University of Rome, Rome, Italy

8. 8Department of Translational and Precision Medicine, Azienda Policlinico Umberto I, Sapienza University of Rome, Rome, Italy

9. 9Department of Clinical and Biological Sciences, University of Turin, Orbassano, Turin, Italy

10. 10Clinical Trial Center, Translational Research and Phase I Unit, Azienda Socio Sanitaria Territoriale Spedali Civili di Brescia, Brescia, Italy

11. 11Division of Hematology, Azienda Ospedaliero Universitaria Policlinico G. Rodolico-S. Marco, Catania, Italy

12. 12Centro Tettamanti, Istituto di Ricovero e Cura a Carattere Scientifico San Gerardo dei Tintori, Monza, Italy

13. 13Department of Molecular Biotechnology and Health Sciences, University of Torino, Italy

14. 14Department of Pathology, Children's Hospital and Harvard Medical School, Boston, MA

15. 15European Institute of Oncology Istituto di Ricovero e Cura a Carattere Scientifico, Division of Haematopathology, Milan, Italy

Abstract

Abstract SETBP1 mutations are found in various clonal myeloid disorders. However, it is unclear whether they can initiate leukemia, because SETBP1 mutations typically appear as later events during oncogenesis. To answer this question, we generated a mouse model expressing mutated SETBP1 in hematopoietic tissue: this model showed profound alterations in the differentiation program of hematopoietic progenitors and developed a myeloid neoplasm with megakaryocytic dysplasia, splenomegaly, and bone marrow fibrosis, prompting us to investigate SETBP1 mutations in a cohort of 36 triple-negative primary myelofibrosis (TN-PMF) cases. We identified 2 distinct subgroups, one carrying SETBP1 mutations and the other completely devoid of somatic variants. Clinically, a striking difference in disease aggressiveness was noted, with patients with SETBP1 mutation showing a much worse clinical course. In contrast to myelodysplastic/myeloproliferative neoplasms, in which SETBP1 mutations are mostly found as a late clonal event, single-cell clonal hierarchy reconstruction in 3 patients with TN-PMF from our cohort revealed SETBP1 to be a very early event, suggesting that the phenotype of the different SETBP1+ disorders may be shaped by the opposite hierarchy of the same clonal SETBP1 variants.

Publisher

American Society of Hematology

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3